Story perspectives

Variant Bio Launches AI to Revolutionize Drug Discovery

1/7/2026

Summary

Story summary

Variant Bio launched an AI platform called Inference to identify new drug candidates for human trials, supporting the U.S. FDA's goal to reduce animal testing.
The platform uses autonomous AI to analyze genetic data from global studies and is now available to research partners.
Variant Bio entered a multi-year collaboration with Boehringer Ingelheim to develop drugs for kidney disease, potentially earning over $120 million.
Collaborations involving the platform exceed $200 million, with other drugmakers like Eli Lilly also adopting AI for drug discovery.

1 of 1

Story summary

Variant Bio launched an AI platform called Inference to identify new drug candidates for human trials, supporting the U.S. FDA's goal to reduce animal testing.
The platform uses autonomous AI to analyze genetic data from global studies and is now available to research partners.
Variant Bio entered a multi-year collaboration with Boehringer Ingelheim to develop drugs for kidney disease, potentially earning over $120 million.
Collaborations involving the platform exceed $200 million, with other drugmakers like Eli Lilly also adopting AI for drug discovery.